BRIEF-Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing Agreement

Reuters

Feb 17

Feb 17 (Reuters) - Twist Bioscience Corp TWST.O:

TWIST BIOSCIENCE EXPANDS ANTIBODY DISCOVERY OFFERING WITH BISPECIFIC LICENSING AGREEMENT
TWIST BIOSCIENCE CORP - ENTERS LICENSING AGREEMENT WITH INVENRA
TWIST BIOSCIENCE CORP - TAKES 6% OWNERSHIP IN INVENRA FOR $13.8 MILLION IN STOCK
TWIST BIOSCIENCE CORP - TO PAY INVENRA 20% ROYALTY ON LICENSE REVENUE

Source text: ID:nBwc2J4mWa

Further company coverage: TWST.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612454300"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612454300\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612454300?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612454300","market":"fut","top_or_hot":-1,"title":"BRIEF-Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing Agreement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing Agreement</title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/TWST\">Twist Bioscience Corp</a> <span>TWST.O</span>:</p><ul><li><p>TWIST BIOSCIENCE EXPANDS ANTIBODY DISCOVERY OFFERING WITH BISPECIFIC LICENSING AGREEMENT</p></li><li><p>TWIST BIOSCIENCE CORP - ENTERS LICENSING AGREEMENT WITH INVENRA</p></li><li><p>TWIST BIOSCIENCE CORP - TAKES 6% OWNERSHIP IN INVENRA FOR $13.8 MILLION IN STOCK</p></li><li><p>TWIST BIOSCIENCE CORP - TO PAY INVENRA 20% ROYALTY ON LICENSE REVENUE</p></li></ul><p>Source text: <span>ID:nBwc2J4mWa</span></p><p>Further company coverage: <span>TWST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-17 20:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing Agreement</title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/TWST\">Twist Bioscience Corp</a> <span>TWST.O</span>:</p><ul><li><p>TWIST BIOSCIENCE EXPANDS ANTIBODY DISCOVERY OFFERING WITH BISPECIFIC LICENSING AGREEMENT</p></li><li><p>TWIST BIOSCIENCE CORP - ENTERS LICENSING AGREEMENT WITH INVENRA</p></li><li><p>TWIST BIOSCIENCE CORP - TAKES 6% OWNERSHIP IN INVENRA FOR $13.8 MILLION IN STOCK</p></li><li><p>TWIST BIOSCIENCE CORP - TO PAY INVENRA 20% ROYALTY ON LICENSE REVENUE</p></li></ul><p>Source text: <span>ID:nBwc2J4mWa</span></p><p>Further company coverage: <span>TWST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUABM4HYY:1","article_id":"2612454300","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612454300","pubTimestamp":1771331231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing AgreementFeb 17 (Reuters) - Twist Bioscience Corp TWST.O:TWIST BIOSCIENCE EXPANDS ANTIBODY DISCOVERY OFFERING WITH ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4588":"碎股","TWST":"Twist Bioscience Corp","BK4585":"ETF&股票定投概念"},"translate_title":"BRIEF-Twist Bioscience通过双特异性许可协议扩大抗体发现产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":0.9},"content_text":"BRIEF-Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing AgreementFeb 17 (Reuters) - Twist Bioscience Corp TWST.O:TWIST BIOSCIENCE EXPANDS ANTIBODY DISCOVERY OFFERING WITH BISPECIFIC LICENSING AGREEMENTTWIST BIOSCIENCE CORP - ENTERS LICENSING AGREEMENT WITH INVENRATWIST BIOSCIENCE CORP - TAKES 6% OWNERSHIP IN INVENRA FOR $13.8 MILLION IN STOCKTWIST BIOSCIENCE CORP - TO PAY INVENRA 20% ROYALTY ON LICENSE REVENUESource text: ID:nBwc2J4mWaFurther company coverage: TWST.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}